A prothrombin gene mutation test is a genetic blood test that detects mutations (most commonly G20210A) in the F2 (prothrombin) gene. The mutation can raise prothrombin levels and increase risk of venous blood clots. It’s used for unexplained thrombosis, recurrent pregnancy loss, or a family history of clotting. Results guide risk assessment, counselling, and management decisions such as anticoagulation or hormonal therapy precautions.

Treatment depends on clinical context. For acute venous thromboembolism, start anticoagulation (initial LMWH or DOACs) then transition to long-term oral anticoagulant; duration is typically 3 months for a provoked VTE and longer or indefinite for unprovoked/recurrent events. In pregnancy or postpartum, prophylactic LMWH is used; avoid estrogen-containing contraceptives. Manage modifiable risks and discuss individualized therapy with a hematologist.

A gene mutation blood test analyzes DNA from a blood sample to detect inherited or acquired genetic changes. It can identify disease-causing mutations, assess hereditary cancer risk, guide targeted therapies and drug choices, confirm diagnoses, and monitor residual disease or recurrence. Results help with risk assessment, family planning, treatment selection and monitoring response or relapse.

The prothrombin (G20210A) gene mutation test is a DNA assay performed on whole blood collected in an EDTA tube — the lavender (purple) top. EDTA preserves leukocyte DNA and prevents clotting; labs typically request 3–10 mL of blood, mixed gently, and sent to the molecular laboratory at room temperature following specimen-handling guidelines.

A positive gene mutation test means a change was found in your DNA associated with increased risk for a specific condition. It doesn’t guarantee disease—risk depends on variant type (pathogenic, likely pathogenic, or uncertain). Results can change screening, prevention, and treatment plans and may affect relatives. See a genetic counselor to interpret the finding, plan follow-up, and arrange family testing.

A prothrombin test (PT/INR) measures how quickly blood clots, assessing the extrinsic coagulation pathway. It’s essential for monitoring warfarin therapy and guiding anticoagulant dosing, detecting clotting-factor or vitamin K deficiencies, and identifying liver dysfunction. It also evaluates bleeding risk before procedures; abnormal results lead to further testing and treatment to prevent excessive bleeding or dangerous clots.